PT  - JOURNAL ARTICLE
AU  - Lasek-Nesselquist, Erica
AU  - Lapierre, Pascal
AU  - Schneider, Erasmus
AU  - George, Kirsten St.
AU  - Pata, Janice
TI  - The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State
AID  - 10.1101/2021.02.26.21251868
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.26.21251868
4099  - http://medrxiv.org/content/early/2021/03/01/2021.02.26.21251868.short
4100  - http://medrxiv.org/content/early/2021/03/01/2021.02.26.21251868.full
AB  - The E484K mutation in the spike protein of SARS CoV-2 contributes to immune escape from monoclonal antibodies as well as neutralizing antibodies in COVID-19 convalescent plasma. It appears in two variants of concern – B.1.351 and P.1 - but has evolved multiple times in different SARS-CoV-2 lineages, suggesting an adaptive advantage. Here we report on the emergence of a 484K variant in the B.1.526 lineage that has recently become prevalent in New York State, particularly in the New York City metropolitan area. In addition to the E484K mutation, these variants also harbor a D235G substitution in spike that might help to reduce the efficacy of neutralizing antibodies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementInitial funding for sequencing was generously provided by the New York Community Trust. This publication was also supported by Cooperative Agreement number NU50CK000516, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the New York State Department of Health Institutional Review Board, under study numbers 02-054 and 07-022.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome sequences and metadata are available at GISAID.org